PTPRD and non-small cell lung carcinoma: The results showed that the PTPRD/PTPRT mutant patients experienced significantly longer OS than WT patients with NSCLC (P = 0.0292) (Supplementary Figure 2A) and SKCM (P = 0.0018) (Supplementary Figure 2B).